Clinical Trial: Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
Study Status: Completed
Recruit Status: RECRUITING
Condition: Septic Shock
Study Type: INTERVENTIONAL
Official Title: DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) Pilot: Serum Biomarkers to Predict Response to Angiotensin II vs. Standard-of-care Vasopressor Therapy in the Treatment of Septic Shock
Brief Summary:
This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of the ability of novel biomarkers (renin and DPP3) to predict blood pressure response to angiotensin II.Given our angiotensin II will be compared to SOC, this will be an unblinded study.
Read more